Affiliation:
1. City Eye Centre Brisbane Australia
2. Royal Brisbane and Women's Hospital Brisbane Australia
3. Faculty of Medicine University of Queensland Saint Lucia Queensland Australia
Abstract
AbstractAge‐related macular degeneration is a global disease with a significant societal impact. The advent of anti‐vascular endothelial growth factor therapy (anti‐VEGF) has revolutionised the treatment of neovascular age‐related macular degeneration (nAMD). Dry age‐related macular degeneration (dAMD) is being investigated for possible therapeutic options. The therapeutic categories undergoing clinical trials include complement pathway inhibitors, visual cycle modulators, reduction of toxic byproducts, antioxidative therapy, neuroprotective agents, laser therapy, surgical options, gene therapy, stem cell therapy, and miscellaneous treatments. Two intravitreal anti‐complement factors (pegcetacoplan and avacincaptad pegol) have recently shown phase 3 clinical trial evidence of a reduction in the growth of geographic atrophy. In this review, we provide an update on treatment options currently undergoing clinical research trials for the management of dAMD and preventing the progression of Geographic Atrophy (GA).
Reference98 articles.
1. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis
2. Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT
3. Clinical Classification of Age-related Macular Degeneration
4. Complement cascade inhibition in geographic atrophy: a review
5. Apellis Pharmaceuticals Inc.Study to Compare the Efficacy and Safety of Intravitreal APL‐2 Therapy With Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age‐Related Macular Degeneration. ClinicalTrials.gov identifier: NCT03525600. Updated June 22 2022.https://clinicaltrials.gov/ct2/show/NCT03525600. Accessed November 1 2022.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献